Disease status stratification individualizes radioiodine therapy for differentiated thyroid cancer: a prospective, multicenter, real-world study

Recurrence risk stratification system-guided radioiodine (131I) therapy of differentiated thyroid cancer (DTC) has fallen into dilemma due to its poor feasibility and insufficient justification. Subjects referred for 131I therapy were consecutively labeled with no evidence of disease, unexplained hyperthyroglobulinemia, or known disease based on stimulated serum thyroglobulin, radioiodine uptake, and medical imaging, and then assigned to radioiodine remnant ablation (RRA), radioiodine adjuvant t